Strong Test Performance

Strong Test Performance Drives Clinical Utility

Corus™ CAD helps physicians minimize the risk of not detecting patients with obstructive* coronary artery disease (CAD).

High Sensitivity and Negative Predictive Value

In the clinical validation study, Corus CAD delivered strong performance.1

  • Sensitivity†: 85%

  • Negative Predictive Value†: 83%

Corus CAD Enables Reclassification

Corus CAD helps physicians decrease the rate of false negative and false positive classifications by clinical factors alone.‡

Reclassification

In the validation study:

  • Overall patient reclassification was correct 75% of the time, as determined by invasive QCA
  • 33% of the false negative classifications by clinical factors were correctly reclassified as having high likelihood of obstructive coronary artery disease by Corus CAD
  • 26% of the false positive classifications by clinical factors were correctly reclassified as having low likelihood of obstructive coronary artery disease by Corus CAD

 More Corus CAD Benefits.

* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).
† Performance associated with a Corus CAD score threshold of 14.75. Corus CAD patient scores range between 0 and 40.
‡ Clinical factors as defined by Diamond-Forrester method.2

  1. PREDICT trial. Clinical trial summary found at: www.clinicaltrials.gov, NCT00500617.
  2. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979. 300(24): p. 1350-8.
    3.